782.9500 16.05 (2.09%)
NSE Oct 28, 2026 14:12 PM
Volume: 90,305
 

Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended